# Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

> **NCT05660083** · PHASE2 · RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 36 (estimated)

## Conditions studied

- HER2-negative Breast Cancer
- Metastatic Breast Cancer
- Metaplastic Breast Carcinoma
- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** L-NMMA

## Key facts

- **NCT ID:** NCT05660083
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-12
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-12-02
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05660083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05660083, "Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05660083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*